Related Experiment Video

Updated: Mar 18, 2026

Author Spotlight: Unveiling Transmembrane Protein Family-Related Markers in Gastric Cancer and Implications for Targeted Therapies
07:47

Author Spotlight: Unveiling Transmembrane Protein Family-Related Markers in Gastric Cancer and Implications for Targeted Therapies

Published on: September 15, 2023

2.3K

Targeting the WEE1 kinase as a molecular targeted therapy for gastric cancer

Hye-Young Kim1,2, Yunhee Cho1,3, HyeokGu Kang1,3

  • 1Department of Biochemistry & Molecular Biology, Yonsei University College of Medicine, Seodaemun-gu, Seoul 03722, Korea.

Oncotarget
|July 1, 2016
PubMed

Insights

Wee1 (Serine/Threonine protein kinase) is highly expressed in gastric cancer, promoting proliferation and metastasis. Targeting Wee1 with AZD1775, alone or combined with chemotherapy, shows therapeutic potential for gastric cancer treatment.

Area of Science:

  • Oncology
  • Molecular Biology
  • Cell Cycle Regulation

Background:

  • Wee1 kinase is a Serine/Threonine protein kinase regulating cell cycle progression.
  • WEE1 is oncogenic in various cancers but unstudied in gastric cancer.
  • Gastric cancer remains a significant global health challenge requiring novel therapeutic targets.

Purpose of the Study:

  • To investigate the oncogenic role of WEE1 in gastric cancer.
  • To evaluate the therapeutic potential of targeting WEE1 in gastric cancer.
  • To assess combination therapies involving WEE1 inhibition.

Main Methods:

  • Analysis of WEE1 expression in gastric cancer patient data.
  • In vitro studies involving WEE1 gene ablation and overexpression in gastric cancer cell lines.
  • In vitro and in vivo efficacy studies of the WEE1 inhibitor AZD1775, alone and in combination with 5-fluorouracil or Paclitaxel.

Main Results:

  • Higher WEE1 expression correlated with lower survival in stage 4 and male gastric cancer patients with lymph node metastasis.
  • WEE1 ablation reduced gastric cancer cell proliferation, migration, and invasion; overexpression enhanced these.
  • AZD1775 inhibited proliferation, induced apoptosis, and caused cell cycle arrest in gastric cancer cells, particularly those with high WEE1 expression.
  • Combination treatments with AZD1775 and chemotherapy agents significantly inhibited tumor growth in vivo.

Conclusions:

  • WEE1 is overexpressed in gastric cancer and drives proliferation and metastasis.
  • Targeting WEE1 with AZD1775 represents a promising therapeutic strategy for gastric cancer.
  • Combination therapy with WEE1 inhibitors may enhance treatment efficacy and safety.
Keywords:
5-FUAZD1775 (MK-1775)PaclitaxelWEE1gastric cancer

More Related Videos

Therapeutic Gene Delivery and Transfection in Human Pancreatic Cancer Cells using Epidermal Growth Factor Receptor-targeted Gelatin Nanoparticles08:35

Therapeutic Gene Delivery and Transfection in Human Pancreatic Cancer Cells using Epidermal Growth Factor Receptor-targeted Gelatin Nanoparticles

Published on: January 4, 2012

28.8K
Utilizing 18F-FDG PET/CT Imaging and Quantitative Histology to Measure Dynamic Changes in the Glucose Metabolism in Mouse Models of Lung Cancer06:51

Utilizing 18F-FDG PET/CT Imaging and Quantitative Histology to Measure Dynamic Changes in the Glucose Metabolism in Mouse Models of Lung Cancer

Published on: July 21, 2018

18.8K

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
9.1K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

1.7K
Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
8.3K
Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
6.1K
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
5.0K